MVP方案加或不加光量子血液疗法治疗晚期非小细胞肺癌  

MVP Regimen with or without Photohemotherapy in Treatment of Advanced Non-small Cell Lung Cancer

作　　者：胡永军[1] 刘爱琴[2] 陈凤军[1] 陈素华[1] 

机构地区：[1]淄博矿务局中心医院肿瘤内科,山东淄博255120 [2]北京军区总医院肿瘤内科

出　　处：《临床肿瘤学杂志》2004年第3期253-255,257,共4页Chinese Clinical Oncology

摘　　要：目的 :观察MVP方案加光量子血液疗法治疗晚期非小细胞肺癌 (NSCLC)的近期疗效和毒副作用。方法 :将 4 8例晚期NSCLC患者随机分为治疗组和对照组 ,分别接受MVP方案 (丝裂霉素、西艾克、顺铂 )及化疗当日开始光量子血液治疗法或单纯MVP方案化疗。结果 :治疗组部分缓解率 5 4 2 % ,对照组 2 5 0 % (P <0 0 5 ) ,中位缓解期分别为 5 1个月及 4 2个月。治疗组毒性明显小于对照组。结论 :MVP方案化疗同时应用光量子血液疗法治疗晚期NSCLC ,疗效有所提高 ,毒性有所减少。Objective:To observe the response rate and toxicity of MVP regimen with or without photohemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).Methods:Forty-eight patients with advanced NSCLC were randomly divided into treatment group and control group receiving MVP regimen (mitomycin c, Vindesine, cisplatin) plus photohemotherapy or MVP regimen alone respectively.Results:The partial response rate was 54.2% in treatment group and 25.0% in control group (P<0.05). The median response duration was 5.1 months and 4.2 months in these two groups respectively. The toxicity in the treatment group was less than that of the control group.Conclusion:MVP combination regimen with photohemotherapy can improve the therapeutic effect of advanced NSCLC without increase of toxicity.

关 键 词：MVP方案 光量子血液疗法 治疗 晚期非小细胞肺癌 毒副作用 丝裂霉素 西艾克 顺铂 

分 类 号：R734.2[医药卫生—肿瘤] R730.5[医药卫生—临床医学]